WO2004042077A3 - Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b) - Google Patents

Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b) Download PDF

Info

Publication number
WO2004042077A3
WO2004042077A3 PCT/EP2003/011883 EP0311883W WO2004042077A3 WO 2004042077 A3 WO2004042077 A3 WO 2004042077A3 EP 0311883 W EP0311883 W EP 0311883W WO 2004042077 A3 WO2004042077 A3 WO 2004042077A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
pde8b
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2003/011883
Other languages
French (fr)
Other versions
WO2004042077A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Priority to AU2003279323A priority Critical patent/AU2003279323A1/en
Priority to EP03772262A priority patent/EP1601782A2/en
Publication of WO2004042077A2 publication Critical patent/WO2004042077A2/en
Publication of WO2004042077A3 publication Critical patent/WO2004042077A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Abstract

The invention provides a human PDE8B which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, endocrinological disease, urological disorders, reproduction disorders and metabolic disease. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, endocrinological disease, urological disorders, reproduction disorders and metabolic disease. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE8B as well as pharmaceutical compositions comprising such compounds.
PCT/EP2003/011883 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b) WO2004042077A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003279323A AU2003279323A1 (en) 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b)
EP03772262A EP1601782A2 (en) 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02024999 2002-11-08
EP02024999.1 2002-11-08

Publications (2)

Publication Number Publication Date
WO2004042077A2 WO2004042077A2 (en) 2004-05-21
WO2004042077A3 true WO2004042077A3 (en) 2005-01-13

Family

ID=32309323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011883 WO2004042077A2 (en) 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b)

Country Status (3)

Country Link
EP (1) EP1601782A2 (en)
AU (1) AU2003279323A1 (en)
WO (1) WO2004042077A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404998B1 (en) 2005-09-02 2015-11-11 Kyoto University Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
CN101960309A (en) 2008-01-17 2011-01-26 东丽株式会社 Composition and method for diagnosis or detection of gastric cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932423A (en) * 1996-03-25 1999-08-03 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterases
US6080548A (en) * 1997-11-19 2000-06-27 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterases
WO2000077040A2 (en) * 1999-06-16 2000-12-21 Incyte Genomics, Inc. Human intracellular signaling molecules
WO2001098471A2 (en) * 2000-06-22 2001-12-27 Incyte Genomics, Inc. Human phosphodiesterases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932423A (en) * 1996-03-25 1999-08-03 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterases
US6080548A (en) * 1997-11-19 2000-06-27 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterases
WO2000077040A2 (en) * 1999-06-16 2000-12-21 Incyte Genomics, Inc. Human intracellular signaling molecules
WO2001098471A2 (en) * 2000-06-22 2001-12-27 Incyte Genomics, Inc. Human phosphodiesterases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI; 21 December 2000 (2000-12-21), XP002283156, retrieved from EBI Database accession no. AAB64411 *
DATABASE EMBL [online] EBI; 27 December 2001 (2001-12-27), XP002283155, retrieved from EBI Database accession no. ABB09006 *
DATABASE EMBL [online] EBI; 27 February 2000 (2000-02-27), XP002283154, retrieved from EBI Database accession no. AAB11938 *
HAYASHI M ET AL: "Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 250, no. 3, 29 September 1998 (1998-09-29), pages 751 - 756, XP002091362, ISSN: 0006-291X *
HAYASHI MASAAKI ET AL: "Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 297, no. 5, 11 October 2002 (2002-10-11), pages 1253 - 1258, XP002255295, ISSN: 0006-291X *
PEREZ-TORRES S ET AL: "Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization.", EXPERIMENTAL NEUROLOGY, vol. 182, no. 2, August 2003 (2003-08-01), pages 322 - 334, XP002283149, ISSN: 0014-4886 *
See also references of EP1601782A2 *

Also Published As

Publication number Publication date
WO2004042077A2 (en) 2004-05-21
EP1601782A2 (en) 2005-12-07
AU2003279323A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
WO2004104216A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2004042389A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2003093816A3 (en) Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2004042077A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2004042390A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
WO2004081563A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
WO2004029617A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a)
WO2003096020A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2004038407A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
WO2004073587A3 (en) Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1)
WO2003066077A3 (en) Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
WO2004071393A3 (en) Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r)
WO2004042076A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4a (pde4a)
WO2003100434A3 (en) Diagnostic and therapeutic use of the arginine vasopressin receptor 2 (avpr2)
WO2004042405A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
WO2004038416A8 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6)
WO2006013016A3 (en) Diagnostics and therapeutics for diseases associated with eosinophil serine protease 1 (prss21)
WO2004071394A3 (en) Diagnostics and therapeutics for diseases associated with hm74
WO2004050903A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4c (pde4c)
WO2005029086A3 (en) Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a10 (ust3-like2) (slc22a10)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003772262

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003772262

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP